Form D · Pharmaceuticals

Medication Review, Inc.

Spokane, WA · CIK 0001497310

Offering snapshot reported Mar 22, 2012 · SEC filing

Reported sold
$12K
Offering amount: $2.5M
Investors reported
1
Form D · investor count
Minimum accepted
$10K
Reported outside-investor minimum
First sale
Mar 19, 2012
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 22, 2012Initial$12,000No comparison1SEC filing
Sep 21, 2010Initial$195,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06, 46
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-175395

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Medication Review, Inc.None

Source: Form D, filed Mar 22, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael R. Anderegg Executive
K. Douglas Crafton Director, Executive
Kyle Downey, Pharm D Executive
Linda Garrelts Mac Lean, B Pharm, R Ph Director
Adam Gelhausen Executive
Mary R Giannini Director
Dennis Hake Executive
Tom Jensen, Mpa Director
James F Karel, Ms Director
Christopher Terriff, R Ph Executive
Chris Terriff, R Ph Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
104 S. Freya Suite 217 White Flag Building
Spokane, WA, 99202